This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Recolony AG


The intestinal microbiota is instrumental to shape our immune system and its functions. At Recolony, we aim to harness the potential of beneficial gut microbiota and to develop a new class of cancer immunotherapy. In that effort, we identified specific bacterial species that are less abundant in CRC patients compared to healthy individuals. Oral supplementation of these bacteria causes a very effective anti-tumor activity in various cancer models through specific activation of cytotoxic T-cells.

We're bringing you

  • Startup spotlight pitch competition